重组改良安卡拉痘苗病毒表达单一非洲马瘟病毒VP2抗原联合接种马匹诱导交叉反应性病毒中和抗体
非洲马瘟是库蠓传播的马属动物致死性病毒病,现有减毒活疫苗存在生物安全与DIVA缺陷。研究用表达AHSV 4型或9型单一VP2蛋白的重组MVA病毒免疫马匹,同时接种比序贯接种更有效,后续加用MVA-VP2(5)可诱导针对4、5、6、8、9型的病毒中和抗体,提示基于MVA-VP2联合的多价免疫方案可行。
要点
- MVA-VP2(4)与MVA-VP2(9)联合接种诱导针对同源AHSV 4型和9型的病毒中和抗体。
- 同时接种两种重组MVA病毒比序贯接种免疫效果更高效。
- 加用MVA-VP2(5)后诱导针对AHSV 4、5、6、8、9型的病毒中和抗体。
核心结论
- 基于MVA-VP2病毒联合的多价AHSV疫苗接种方案是可行的。
研究设计与样本
- 研究用表达AHSV 4型或9型单一VP2蛋白的重组MVA病毒(分别记为MVA-VP2(4)和MVA-VP2(9))免疫马匹,并比较同时接种与序贯接种,随后对已接种MVA-VP2(4)和MVA-VP2(9)的小马在4个月后给予第三和第四剂表达AHSV 5型VP2的MVA。
主要发现
- 接种MVA-VP2(4)和MVA-VP2(9)诱导了针对同源AHSV 4型和9型的病毒中和抗体。
- 同时接种疫苗比序贯接种免疫效果更高效。
- 对先前接种MVA-VP2(4)和MVA-VP2(9)的小马在4个月后给予MVA-VP2(5)加强,诱导了针对AHSV 4、5、6、8和9型的病毒中和抗体。
- 针对AHSV 9和AHSV 4的回忆性抗体反应提示不同血清型之间可能存在一些共享表位。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
African horse sickness is a lethal viral disease of equids transmitted by biting midges of the Genus Culicoides. The disease is endemic to sub-Saharan Africa but outbreaks of high mortality and economic impact have occurred in the past in non-endemic regions of Africa, Asia and Southern Europe. Vaccination is critical for the control of this disease but only live attenuated vaccines are currently available. However, there are bio-safety concerns over the use of this type of vaccines, especially in non-endemic countries, and live attenuated vaccines do not have DIVA (Differentiation of Infected from Vaccinated Animals) capacity. In addition, large scale manufacturing of live attenuated vaccines of AHSV represents a significant environmental and health risk and level 3 bio-safety containment facilities are required for their production. A variety of different technologies have been investigated over the years to develop alternative AHSV vaccines, including the use of viral vaccine vectors such Modified Vaccinia Ankara virus (MVA). In previous studies we demonstrated that recombinant MVA expressing outer capsid protein AHSV-VP2 induced virus neutralising antibodies and protection against virulent challenge both in a mouse model and in the horse. However, AHSV-VP2 is antigenically variable and determines the existence of 9 different AHSV serotypes. Immunity against AHSV is serotype-specific and there is limited cross-reactivity between certain AHSV serotypes: 1 and 2, 3 and 7, 5 and 8, 6 and 9. In Africa, multiple serotypes circulate simultaneously and a polyvalent attenuated vaccine comprising different AHSV serotypes is used. We investigated the potential of a polyvalent AHSV vaccination strategy based on combinations of MVA-VP2 viruses each expressing a single VP2 antigen from a specific serotype. We showed that administration of 2 different recombinant MVA viruses, each expressing a single VP2 protein from AHSV serotype 4 or 9, denoted respectively as MVA-VP2(4) and MVA-VP2(9), induced virus neutralising antibodies against the homologous AHSV serotypes. Vaccination was more efficient when vaccines were administered simultaneously than when they were administered sequentially. A third and fourth dose of a different MVA expressing VP2 of AHSV serotype 5, given 4months later to ponies previously vaccinated with MVA-VP2(4) and MVA-VP2(9), resulted in the induction of VNAb against serotypes 4, 5, 6, 8 and 9. The anamnestic antibody response against AHSV 9 and AHSV 4 following the MVA-VP2(5) boost suggests that it is possible some shared epitopes exist between different serotypes. In conclusion this study showed that it is feasible to develop a polyvalent AHSV vaccination regime based on the use of combinations of MVA-VP2 viruses.
引用
- Manning NM, Bachanek-Bankowska K, Mertens PPC, et al. Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination. Vaccine. 2017. PMID: 28438410. doi:10.1016/j.vaccine.2017.04.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。